Dr. Jin-an Jiao has served as Synthekine’s Vice President of Process and Analytical Development since June 2022, overseeing development for Synthekine’s biologics and cell therapy programs. Jin-an has 30 years of experience in development of protein therapeutics, particularly in such areas as development of downstream purification methods, formulation and stability studies, non-clinical studies, analytical assay development and more. Prior to joining Synthekine, he was Vice President of Development at HCW Biologics and Altor Bioscience. Prior to Altor, Dr. Jiao was Chief Scientific Officer at SAB Biotherapeutics. Previously, he served as Executive Vice President of Product Development and Manufacturing at Hematech Inc. During his career at Hematech and SAB Biotherapeutics, Dr. Jiao made significant contributions to the development of a novel transchromosomal bovine technology platform to produce fully human antibodies against a variety of emerging infectious diseases. Before Hematech, he was the Director of Protein Development at Sunol Molecular Corporation. Dr. Jiao holds a Ph.D. in Biochemistry from the University of Nebraska-Lincoln and conducted postdoctoral training at the University of California-Berkeley.